Struggles with obesity are a longstanding issue for millions of Americans and thousands of Iowans, but recent advancements in ...

Barriers to accessing GLP-1 medications are beginning to break down as drug manufacturers, insurers, and lawmakers look to expand availability, lower costs, and address continued high demand.

Imagine a world where diabetes could be treated with a simple pill that essentially reprograms your body to produce insulin ...

American doctors tracking women being treated for an aggressive form of breast cancer have discovered the drug 'detrimentally affects' how the body responds to cancer treatments.

While GLP-1 receptor agonist medications like Ozempic, Semaglutide, and Wegovy have transformed the weight loss landscape, SlimCell offers a complementary, all-natural solution to help maintain and ...

November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) ...

CELLEV8 Launches First Post-GLP-1 Gummy Supplement: "SlimCell™" with Clinically Proven Ingredients to Compliment GLP-1 ...

Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

Glucagon-like peptide 1 receptor agonists and fenofibrates may protect patients with type 2 diabetes against diabetic macular ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart ...